This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Verastem’s 8K filing here.
About Verastem
Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Further Reading
- Five stocks we like better than Verastem
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- How to Calculate Return on Investment (ROI)
- 3 Buy-and-Hold Stocks for Long-Term Growth
- How to Invest in Small Cap Stocks
- Despite Short-Term Risks Freeport McMoran Worth a Look
